Paper16670306
OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity.
Soroosh P and 3 others. J Immunol, 2006. Cited by 89 papers, by iCite.
Cite this record
ConductScience Library. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. Papers, record 16670306. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16670306
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CD4-Positive T-Lymphocytes | Major topic |
| Cell Communication | Major topic |
| Membrane Glycoproteins | Major topic |
| Receptors, Tumor Necrosis Factor | Major topic |
| Tumor Necrosis Factors | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Cell Survival | |
| Cells, Cultured | |
| Down-Regulation | |
| Female | |
| Lymphocyte Activation | |
| Mice | |
| Mice, Inbred C57BL | |
| Mice, Knockout | |
| Mice, Transgenic | |
| OX40 Ligand | |
| Receptors, OX40 | |
| Signal Transduction | |
| Time Factors |
Source PubMed
Cited by51
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 89 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42579877 | Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/42579877 | PubMed |
| 42344924 | Noncanonical NF-κB pathway driven inflammation across multiple cellular compartments identifies NIK as a therapeutic target for inflammatory bowel disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42344924 | PubMed |
| 41737211 | OX40 signaling in cancer immunotherapy: mechanisms of action, translational applications, and therapeutic perspectives. | Front Immunol | 2026 | https://conductscience.org/library/papers/41737211 | PubMed |
| 41659847 | Prognostic immunological implications of OX40L expression in the tumor microenvironment of melanoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/41659847 | PubMed |
| 41305468 | Association Between FOXP3 and OX40 Expression in Adult T-Cell Leukemia Cells. | Viruses | 2025 | https://conductscience.org/library/papers/41305468 | PubMed |
| 39825223 | Pan-cancer analysis shows that TNFSF4 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including liver cancer. | BMC Cancer | 2025 | https://conductscience.org/library/papers/39825223 | PubMed |
| 39715901 | Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors. | Nat Biomed Eng | 2024 | https://conductscience.org/library/papers/39715901 | PubMed |
| 39363128 | Tumor necrosis factor superfamily signaling: life and death in cancer. | Cancer Metastasis Rev | 2024 | https://conductscience.org/library/papers/39363128 | PubMed |
| 38440738 | Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake. | Front Immunol | 2024 | https://conductscience.org/library/papers/38440738 | PubMed |
| 37939656 | The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. | Cell Metab | 2023 | https://conductscience.org/library/papers/37939656 | PubMed |
| 37752152 | YAP1 expression is associated with survival and immunosuppression in small cell lung cancer. | Cell Death Dis | 2023 | https://conductscience.org/library/papers/37752152 | PubMed |
| 36911729 | NFκB signaling in T cell memory. | Front Immunol | 2023 | https://conductscience.org/library/papers/36911729 | PubMed |
| 36453632 | Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. | Blood Adv | 2023 | https://conductscience.org/library/papers/36453632 | PubMed |
| 36211974 | Adenoviral delivery of soluble ovine OX40L or CD70 costimulatory molecules improves adaptive immune responses to a model antigen in sheep. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36211974 | PubMed |
| 35352295 | Current Clinical Trial Landscape of OX40 Agonists. | Curr Oncol Rep | 2022 | https://conductscience.org/library/papers/35352295 | PubMed |
| 35286699 | The Immunogenetics of Systemic Sclerosis. | Adv Exp Med Biol | 2022 | https://conductscience.org/library/papers/35286699 | PubMed |
| 35286698 | Immunogenetics of Lupus Erythematosus. | Adv Exp Med Biol | 2022 | https://conductscience.org/library/papers/35286698 | PubMed |
| 35265719 | Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis. | J Immunol Res | 2022 | https://conductscience.org/library/papers/35265719 | PubMed |
| 34900670 | Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment. | Front Oncol | 2021 | https://conductscience.org/library/papers/34900670 | PubMed |
| 32939048 | Extracellular vesicles produced by immunomodulatory cells harboring OX40 ligand and 4-1BB ligand enhance antitumor immunity. | Sci Rep | 2020 | https://conductscience.org/library/papers/32939048 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16670306
GET https://conductscience.org/api/papers/v1/16670306/cited_by?page=2